Histalex (Chlorphenamine maleate) is generally used for providing symptomatic relief across domains where additional symptomatic support is needed. The medication is relevant in clinical settings marked by increased discomfort or tension due to allergies. It helps ease the overall symptom burden, particularly when symptoms create noticeable physiological strain.

The core application of Histalex is in managing conditions characterized by periods of heightened symptoms, such as allergic rhinitis (hay fever and perennial allergies), urticaria (hives), and allergic conjunctivitis. This relief supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods.

The medication is commonly used to help with symptom clusters that may become disruptive, including frequent sneezing, excessive runny nose, itchy eyes, and generalized pruritus (itching). It is often used when symptoms intensify and supportive relief is needed, or when symptoms become temporarily overwhelming due to acute allergic flare-ups. This provides supportive relief when symptoms interfere with routine activities.

“The medication provides supportive relief by easing the impact of temporary functional strain caused by symptoms related to irritative or inflammatory states.”

---

Quick Fact: Relief for Pruritus
Histalex is applied across domains where additional symptomatic support is needed to address the itching and sudden skin swelling seen in acute allergic skin reactions and hives.

Regulatory References

1. DailyMed Official Label from the National Institutes of Health (NIH)

Histalex (Chlorphenamine maleate) eligibility is determined by official regulatory documents based on age, concurrent medication, and pre-existing medical conditions.

Contraindications and Prohibited Use

Use is strictly contraindicated for patients with known hypersensitivity to chlorphenamine maleate, and for those taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them. The medicine must not be used in newborn or premature infants. Absolute prohibitions also apply to patients with conditions like narrow-angle glaucoma, urinary retention, pyloroduodenal obstruction, severe hypertension, or severe coronary artery disease.

Age and Conditional Restrictions

• Pediatric Use: The medication is generally not recommended for children under six years of age for some formulations. Liquid forms may be approved for use in younger children down to one year, but use in infants is prohibited.
• Geriatric Use: Caution is required in older adults due to increased susceptibility to neurological effects.
• Pregnancy and Lactation: Use is not recommended during pregnancy, especially in the third trimester. Use is also not recommended for nursing mothers.
• Organ Impairment: Patients with severe hepatic impairment or severe renal impairment must use Histalex only with caution.

Interactions with other medicines and products

This section details the officially documented interaction profile of Histalex (Chlorphenamine maleate), derived strictly from government regulatory sources.

Property	Description
Medicinal product categories with documented interactions:	Monoamine Oxidase Inhibitors (MAOIs); Central Nervous System (CNS) depressants; agents with Anticholinergic properties; drugs metabolised by Cytochrome P450 (CYP) enzymes.
Specific interacting medicines (if explicitly listed):	Phenytoin; Alcohol.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic interaction (additive CNS and anticholinergic effects); Pharmacokinetic interaction (inhibition of hepatic metabolism, specifically CYP2D6); Prolongation and intensification of Histalex effects by MAOIs.
Timing-based interaction rules (if applicable):	Co-administration with MAOIs is prohibited for patients who have received MAOI therapy within the last 14 days.
Population-specific interaction notes (if applicable):	Elderly patients (increased susceptibility to interaction effects); Severe Hepatic Impairment (caution due to potential clearance changes).

Classification	Description
Interaction severity classification:	Contraindicated combination (with MAOIs); Interactions requiring caution/avoidance (with CNS depressants, anticholinergics, alcohol, and phenytoin).
Regulatory basis:	FDA Prescribing Information; EMA Summary of Product Characteristics (SmPC).

Official Interaction Statements

• Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This prohibition extends to MAOIs taken within 14 days of beginning Histalex.
• The medicine exhibits a pharmacokinetic interaction through the inhibition of hepatic metabolism, which results in a documented risk of increased plasma concentration of phenytoin.
• Concurrent administration with other Central Nervous System (CNS) depressants leads to an additive pharmacodynamic effect, resulting in increased sedation and impairment.
• Combined use with agents possessing anticholinergic properties may produce additive anticholinergic adverse effects.
• Consumption of alcohol concurrently with the drug is documented to potentiate the sedative effects of the medicine.

The overall interaction profile is defined by a formal contraindication with MAOIs requiring mandatory time separation and the widespread potential for additive pharmacodynamic effects with other CNS-acting and anticholinergic agents. The profile is further constrained by a documented pharmacokinetic interaction involving the inhibition of drug metabolism.

Modulation of Peripheral H1 Receptor Signaling

Histalex acts within domains involving receptor-mediated signaling by competitively binding to and blocking peripheral histamine H1 receptors on various cells, including smooth muscle and endothelium. This action suppresses the signaling cascade typically initiated by the body's natural chemical messenger, histamine, leading to predictable physiological adjustments like the adjustment of elevated vascular activity.

---

Regulation of Vascular Permeability Pathways

The drug engages mechanisms that influence a mechanistic cascade associated with heightened physiological responses, specifically those involving the small blood vessels. By antagonizing the H1 receptor, Histalex modifies early molecular steps that control vascular permeability and vasodilation, resulting in a reduction in the effect of elevated mediator concentrations and the facilitation of pathway equilibrium restoration.

Histalex is administered primarily via the oral route, commonly supplied as a 4 mg tablet or a 2 mg/5 mL syrup. It is also manufactured as a 10 mg/mL solution for injection, approved for intramuscular (IM), subcutaneous (SC), and slow intravenous (IV) administration in appropriate settings.

For adults, the typical oral dose is 4 mg, which is generally taken every 4 to 6 hours, provided a minimum of four hours separates successive doses. The official maximum dose for oral administration is strictly limited to 24 mg in any 24-hour period. When administered parenterally, the adult dose ranges from 10 mg to 20 mg, with a total 24-hour maximum of 40 mg.

Specific instructions govern the use of Histalex across different forms and populations. The medicine may be taken with or without food. Administration of the injection intravenously must be performed slowly, over a period of at least one minute. Oral liquid forms, particularly for children, require measurement with an accurate milliliter measuring device. Dosage is adjusted based on age: Children 6 to 12 years are given 2 mg per dose, while a lower maximum daily dose of 12 mg is advised for older adults. These instructions establish the standardized procedural framework for using the medicine.

Research Evidence / Overview of Studies

---

Phase 3 Trial Data

Clinical data evaluated the clinical activity of Histalex in adult participants with chronic pain. These studies were randomized, double-blind, and placebo-controlled. The primary outcome measure was a change in the Visual Analog Scale (VAS) for pain intensity.

• Efficacy Trials: Studies investigated outcomes related to pain intensity in adult participants. Initial analysis of the 12-week trials assessed whether Histalex was associated with changes measured at the start of the study period compared to placebo. Secondary outcomes included measurements of physical function and quality of life.
• Tolerability Profile: Research examined the range of adverse events reported during the long-term tolerability study.

---

Mechanism and Pharmacology Studies

Research explored how the compound interacts with biological targets in the inflammatory cascade. The studies involved in vitro and animal models to describe the compound's activity on biological structures.

• Biomarker Research: A key finding reported changes in inflammation markers during the six-month study period in a subset of participants. The clinical significance of this change is not yet clear.
• Drug-Drug Interaction Studies: Studies evaluated potential interactions between Histalex and MAOIs. Research in this area is currently being conducted to assess the pharmacokinetic profile.

---

Administration and Pharmacokinetics

Pharmacokinetic studies evaluated how the body processes the drug, including absorption, distribution, metabolism, and excretion.

• Food Effect: Studies evaluated the effect of taking the medication on an empty stomach versus with food. Results indicated that absorption was slower when taken with a high-fat meal. This data helps characterize the drug's absorption profile under different conditions.
• Hepatic Impairment: Studies examined participants with mild to moderate hepatic impairment to determine if dosage adjustments were necessary. The research evaluated the differences in drug exposure in participants with hepatic impairment.

Key Studies & References

1. Efficacy and Safety of Histalex in Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2. Pharmacokinetics of Histalex in Subjects with Mild to Moderate Hepatic Impairment

Common questions about Histalex (FAQ)

Q: Are there any long-term effects associated with using Histalex for an extended period?

Official guidance often recommends Histalex for use over a limited duration for self-treatment, typically two weeks or less. Information in official documentation suggests that use beyond the recommended short period is intended to occur under the ongoing supervision of a healthcare professional.

Q: Can Histalex be used to treat symptoms beyond just allergies, such as a common cold?

Yes. According to official product information, Histalex is used to provide relief from symptoms associated with allergic conditions, and its uses also include the management of symptoms related to the common cold or the flu, such as sneezing and runny nose.

Q: What happens if I stop taking Histalex suddenly after using it for several months?

Regulatory guidelines indicate that the discontinuation of the medicine should be discussed with a healthcare professional. This is particularly relevant for patients who have been using the medicine for a long period of time.

Q: Why is Histalex sometimes prescribed for skin conditions in addition to seasonal allergies?

The medicine is described in official documents as being useful for treating more than just respiratory allergies. Its indications include the management of hives (urticaria) and the relief of itching associated with various skin diseases, such as dermatitis and eczema.

Q: Can taking Histalex cause unexpected changes in mood or behavior?

Official documentation lists potential changes in mood and behavior among the possible adverse reactions. These reports include feelings of nervousness or sleeplessness, and in some documented instances, more severe mood changes.

Q: How quickly can I expect Histalex to start working after taking it?

Authoritative sources indicate that a reduction in symptoms typically begins within 30 to 60 minutes following the administration of the medicine. This is the period during which the effects of the medicine are generally noticed.

Q: Is there a maximum time frame that a person is permitted to use Histalex?

For over-the-counter use without professional supervision, regulatory guidance advises against using the medicine for more than seven to fourteen days, depending on the specific jurisdiction. If symptoms persist beyond the recommended short duration, consultation with a healthcare professional is noted as appropriate.

Q: Does Histalex need to be taken at a specific time of day to be most effective?

While the medicine's efficacy is not linked to the time of day it is taken, a regulatory statement regarding its safety exists. Due to the potential for drowsiness as a side effect, evening administration is noted in guidance.

Q: Is Histalex safe for breastfeeding women, or is it passed into breast milk?

Official product information states that the use of Histalex is generally not recommended for nursing mothers. Authoritative sources confirm the drug is passed into breast milk, and its use is generally not recommended for nursing mothers.

Q: What is the half-life of Histalex, as described in pharmacology texts?

Pharmacology data in official regulatory portals reports a wide variation in the elimination half-life of the active ingredient. Reported values range from approximately 2 to 43 hours in different individuals.

Q: Is Histalex used for emergency allergy situations, or only for ongoing management?

The primary use of Histalex is for the symptomatic relief of ongoing allergic conditions. However, official documents approve injection forms for subcutaneous, intramuscular, and slow intravenous administration. These administration methods are typically reserved for use in specific clinical settings.

Q: Does Histalex affect sleep patterns or cause insomnia?

Insomnia (difficulty sleeping) is listed among the possible adverse reactions reported in official documents for the medicine. Conversely, drowsiness is one of the most frequently reported side effects.

Q: Are there any specific organs, like the liver or kidneys, that Histalex might affect?

The official label includes a cautionary statement regarding use in individuals with pre-existing severe impairment of the liver or kidneys. Authoritative medical sources generally indicate that the risk of clinically apparent injury to the liver from the active ingredient is exceedingly rare.

Q: What is the legal classification of Histalex (e.g., prescription-only or over-the-counter)?

Histalex is legally classified as an over-the-counter (OTC) medicine in some formulations and countries. However, classification can vary by jurisdiction and specific formulation.

Q: Does Histalex have any known interactions with herbal supplements or vitamins?

Official guidance generally cautions against concurrent use with herbal remedies or supplements that cause side effects similar to the medicine, such as sleepiness or dry mouth, due to the risk of additive effects.

Q: Is it typical for side effects from Histalex to decrease after using it for a few weeks?

Official documentation notes that some common side effects, such as initial drowsiness, are often temporary. These effects typically begin to wear off after a few days as the body adjusts to the medicine.

Q: In the UK, what is the maximum 24-hour dose for the oral tablet form?

Official formularies in the United Kingdom describe the maximum recommended daily oral dose for adults. This limit is set at 24 milligrams in any 24-hour period.

Q: What should I do if I accidentally miss a dose of Histalex?

Regulatory documents detailing specific instructions for a missed dose are not universally provided. Information available suggests that a single missed dose is typically managed by either taking it when remembered or skipping it if close to the next scheduled administration.

Q: Is it safe to take Histalex if I am already taking over-the-counter pain relievers?

Histalex is officially documented to have interactions with certain medicines that are metabolized by the CYP2D6 enzyme or those that are Central Nervous System (CNS) depressants. Concurrent use with certain over-the-counter pain relievers that fall into these categories may require monitoring.

Q: Does taking Histalex interact negatively with common foods or drinks, like coffee or alcohol?

Official documents explicitly caution that consuming alcohol concurrently with Histalex can intensify the medicine's sedative effects. Studies also indicate that taking the medication with a high-fat meal may lead to slower absorption.

Q: Can Histalex affect the results of allergy skin tests?

Because the active ingredient in Histalex works by blocking the H1 receptors that respond to histamine, it may interfere with the results of diagnostic allergy skin tests. It is important for patients to discuss the use of this medicine before undergoing diagnostic allergy skin tests.

Q: Can Histalex be taken on an empty stomach, or is food necessary?

Official administration instructions state that Histalex may be taken either with or without food. While it can be taken on an empty stomach, studies show that absorption may be slower when the medicine is taken with a high-fat meal.

Q: What is the descriptive information regarding use of Histalex during pregnancy?

Regulatory documents advise that use of Histalex is generally not recommended during pregnancy, particularly during the third trimester. This precautionary statement reflects the general risk profile for antihistamines in this setting.

Q: How does Histalex's use conditions differ when treating chronic versus seasonal symptoms?

The core administration instructions, such as dosing frequency, generally apply to the symptomatic relief of allergic conditions. However, the overall duration of use often varies, with seasonal or acute symptoms leading to shorter prescribed courses compared to chronic conditions.

How to Store and Dispose of Histalex?

This section outlines the official, regulatory storage and disposal requirements for Histalex, as documented by governmental health authorities.

Official Storage Requirements

Condition	Requirement
Temperature	Store in a cool place, below 25 C.
Protection	Store in a dry place and a place protected from light.
Child Safety	Keep out of the reach of children.

Storage Profile

Regulatory documentation mandates that Histalex be stored below 25 C to maintain product integrity. Crucially, the medication must be shielded from degradation by storing it in environments that are both dry and protected from light. To ensure safety, the official label requires the medication to be inaccessible to children at all times. No specific disposal instructions are documented in the available official labeling.